Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**HalcyGen Pharmaceuticals Limited**
ABN	**76 115 832 963**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roger Aston
Date of last notice	17 October 2008

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Direct interest (1) Newtonmore Biosciences Pty Ltd (2) Newtonmore Super Fund (3)
Date of change	29 & 30 October 2009
No. of securities held prior to change	5,320,000 Ordinary Shares (1) 4,251,000 Ordinary Shares (2) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2012 (1)
Class	Ordinary fully paid shares (a) Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (b)
Number acquired	1,000,000 (3a) 1,900,000 (1b)
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$200,000 (a) Nil (b)
No. of securities held after change	5,320,000 Ordinary Shares (1) 4,251,000 Ordinary Shares (2) 1,000,000 Ordinary Shares (3) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 625,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2012 (1) 1,900,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (1)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Second Placement Shares issued for part funding of the initial payment required on acquisition of Mayne Pharma International Pty Ltd and to further progress research and development and to augment working capital requirements following the acquisition of Mayne Pharma International Pty Ltd. (a) The Options are being issued to employees and Directors in recognition of the performance and contributions made and the continued success and growth of the Company, in particular with regard to the acquisition of Mayne Pharma International Pty Ltd. (b)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**HalcyGen Pharmaceuticals Limited**
ABN	**76 115 832 963**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Mathieson
Date of last notice	20 February 2008

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1) Mr Bruce Mathieson 2) Mrs Jill Mathieson 3) Investment Holdings Pty Ltd 4) BLM Superannuation Nominees Pty Ltd
Date of change	29 & 30 October 2009
No. of securities held prior to change	250,000 Ordinary Fully Paid Shares (2) 2,647,345 Ordinary Fully Paid Shares (3) 1,090,000 Ordinary Fully Paid Shares (4) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1)
Class	Ordinary fully paid shares (a, b, c and d) Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (e)
Number acquired	7,500,000 (3a) 23,244 (3b) 11,622 (4c) 11,622 (2d) 350,000 (3e)

+ See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$1,500,000 (a) \$4,648.80 (b) \$2,324.40 (c) \$2,324.40 (d) Nil (e)
No. of securities held after change	261,622 Ordinary Fully Paid Shares (2) 10,170,589 Ordinary Fully Paid Shares (3) 1,101,622 Ordinary Fully Paid Shares (4) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 350,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (3)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Second Placement Shares issued for part funding of the initial payment required on acquisition of Mayne Pharma International Pty Ltd and to further progress research and development and to augment working capital requirements following the acquisition of Mayne Pharma International Pty Ltd. (a) Participation in SPP (b, c and d) The Options are being issued to employees and Directors in recognition of the performance and contributions made and the continued success and growth of the Company, in particular with regard to the acquisition of Mayne Pharma International Pty Ltd. (e)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	

Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**HalcyGen Pharmaceuticals Limited**
ABN	**76 115 832 963**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	The Hon Ron Best
Date of last notice	3 July 2007

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1) Ms Louise Asher 2) Bremal Pty Ltd
Date of change	29 and 30 October 2009
No. of securities held prior to change	150,000 Ordinary Fully Paid Shares (2) 750,000 Unlisted options for ordinary shares @ 10 cents expiring 30 June 2010 (2) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (2) 34,000 Ordinary Fully Paid Shares (1)
Class	Ordinary Fully Paid Shares (1 and 2) Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (2)
Number acquired	11,622 (1a) 11,622 (2b) 350,000 (2c)
Number disposed	Nil

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$2,324.40 (a) \$2,324.40 (b) Nil (c)
No. of securities held after change	161,622 Ordinary Fully Paid Shares (2) 750,000 Unlisted options for ordinary shares @ 10 cents expiring 30 June 2010 (2) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (2) 45,622 Ordinary Fully Paid Shares (1) 350,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (2)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in SPP (a and b) The Options are being issued to employees and Directors in recognition of the performance and contributions made and the continued success and growth of the Company, in particular with regard to the acquisition of Mayne Pharma International Pty Ltd. (c)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**HalcyGen Pharmaceuticals Limited**
ABN	**76 115 832 963**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Craig Bottomley
Date of last notice	12 September 2007

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1) Magnum Capital Pty Ltd (1) 2) Sainters Pty Ltd atf Bottomley Superannuation A/c (2)
Date of change	29 October 2009
No. of securities held prior to change	2,250,000 Ordinary Fully Paid Shares (1) 30,000 Ordinary Fully Paid Shares (2) 2,500,000 Unlisted options for ordinary shares @ 10 cents expiring 30 June 2010 (1) 750,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1)
Class	Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (1)
Number acquired	1,400,000
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	2,250,000 Ordinary Fully Paid Shares (1) 2,500,000 Unlisted options for ordinary shares @ 10 cents expiring 30 June 2010 (1) 750,000 Unlisted options for ordinary shares @ 60 cents expiring 17 April 2011 (1) 30,000 Ordinary Fully Paid Shares (2) 1,400,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (1)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Options are being issued to employees and Directors in recognition of the performance and contributions made and the continued success and growth of the Company, in particular with regard to the acquisition of Mayne Pharma International Pty Ltd.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**HalcyGen Pharmaceuticals Limited**
ABN	**76 115 832 963**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Scholes
Date of last notice	14 October 2008

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest (1)
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Direct interest (1) Over the Wavery Hill Superannuation Fund (2) UBS Wealth Management Australia Nominees Pty Ltd (3)
Date of change	29 & 30 October 2009
No. of securities held prior to change	50,000 Ordinary Fully Paid Shares (2) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 30 November 2012 (1)
Class	Ordinary fully paid shares (a & b) Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (c)
Number acquired	250,000 (3a) 11,622 (2b) 350,000 (1c)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$50,000 (a) $2,324.40 (b) Nil. (c)

No. of securities held after change	61,622 Ordinary Fully Paid Shares (2) 250,000 Ordinary Fully Paid Shares (3) 250,000 Unlisted options for ordinary shares @ 60 cents expiring 30 November 2012 (1) 350,000 Unlisted options for ordinary shares @ 27 cents expiring 31 December 2012 (1)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Second Placement Shares issued for part funding of the initial payment required on acquisition of Mayne Pharma International Pty Ltd and to further progress research and development and to augment working capital requirements following the acquisition of Mayne Pharma International Pty Ltd. (a) Participation in SPP (b) The Options are being issued to employees and Directors in recognition of the performance and contributions made and the continued success and growth of the Company, in particular with regard to the acquisition of Mayne Pharma International Pty Ltd. (c)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	

+ See chapter 19 for defined terms.

Interest after change	

+ See chapter 19 for defined terms.